← Back to signals
SPRB
Spruce Biosciences, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
Days to cover (short int.)
7.0d↑+23.1%
as of 2026-10-30 · shares short vs 2026-09-30
Fund 13D/13G Filings (3)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Citadel Advisors | SC 13G/A | −18K | 1.9% | -16.3% vs SPY -18.5% abs | 2026-08-14 | ↗ |
| Citadel Advisors | SC 13G/A | — | 5.1% | -13.0% vs SPY -7.5% abs | 2026-05-15 | ↗ |
| Citadel Advisors | SC 13G/A | — | 6.5% | — | 2026-02-17 | ↗ |
Tracked Funds Holding (1)
| Fund | Manager | Shares Held | Position Value |
|---|---|---|---|
| Point72 | Steve Cohen | 44K | $2M |
Quarter-end 13F positions for the tracked funds holding this stock.